CoChat

Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study

Open access

The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Depression among methamphetamine users is more prevalent in females than males, but gender-specific treatment options for this comorbidity have not been described. Reduced brain phosphocreatine levels have been shown to be lower in female methamphetamine users compared to males, and, of relevance, studies have demonstrated an association between treatment-resistant depression and reduced brain phosphocreatine concentrations. The nutritional supplement creatine monohydrate has been reported to reduce symptoms of depression in female adolescents and adults taking antidepressants, as well as to increase brain phosphocreatine in healthy volunteers. Therefore, the purpose of this pilot study was to investigate creatine monohydrate as a treatment for depression in female methamphetamine users. METHODS: Fourteen females with depression and comorbid methamphetamine dependence were enrolled in an 8-week open label trial of 5 g of daily creatine monohydrate and of these 14, 11 females completed the study. Depression was measured using the Hamilton Depression Rating Scale (HAMD) and brain phosphocreatine levels were measured using phosphorus magnetic resonance spectroscopy pre- and post-creatine treatment. Secondary outcome measures included anxiety symptoms, measured with the Beck Anxiety Inventory (BAI), as well as methamphetamine use, monitored by twice weekly urine drug screens and self-reported use. RESULTS: The results of a linear mixed effects repeated measures model showed significantly reduced HAMD and BAI scores as early as week 2 when compared to baseline scores. This improvement was maintained through study completion. Brain phosphocreatine concentrations were higher at the second phosphorus magnetic resonance spectroscopy scan compared to the baseline scan; Mbaseline = 0.223 (SD = 0.013) vs. Mpost-treatment = 0.233 (SD = 0.009), t (9) = 2.905, p <.01, suggesting that creatine increased phosphocreatine levels. Also, a reduction in methamphetamine positive urine drug screens of greater than 50% was observed by week 6. Finally, creatine was well tolerated and adverse events that were related to gastrointestinal symptoms and muscle cramping were determined as possibly related to creatine. CONCLUSIONS: The current study suggests that creatine treatment may be a promising therapeutic approach for females with depression and comorbid methamphetamine dependence. This study is registered on clinicaltrials.gov (NCT01514630).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/15504263.2015.1100471

Cites

101 of 101 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 101 references

Research works printed but not linked: 7

  1. Bizzarini E., 2004, Journal of Sports Medicine and Physical Fitness, 44, 411
  2. 10.1189/1550-2783-9-99 · doi:10.1189/1550-2783-9-99
  3. 10.1097/jan.000000000000058 · doi:10.1097/jan.000000000000058
  4. Jou S.H., 2009, Chang Gung Medical Journal, 32, 370
  5. 10.1016/j.psychires.2010.10.008 · doi:10.1016/j.psychires.2010.10.008
  6. Lukaszuk J.M., 2005, Journal of Strength and Conditioning Research, 19, 735
  7. McKetin R., 2011, Medical Journal of Australia, 195, S51

Cited by

See all 54

Metadata

Authors
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F.
Affiliations
University of Utah (US)
Corresponding author
Hellem, Tracy L.
Venue
Journal of Dual Diagnosis
Published
2015-10-02
Volume
11
Issue
3-4
Pages
189-202
ISSN
  • 1550-4263 (ISSN-L)
  • 1550-4271
OpenAlex
W2143531665
Cited by
49
References
101
Citations by year
2026: 5 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 2 · 2021: 4 · 2020: 6 · 2019: 5 · 2018: 5 · 2017: 2 · 2016: 3 · 2015: 1
FWCI
2.65
Type
journal article
Language
en
Open access
Locations
  • Journal of Dual Diagnosis (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Gazi Üniversitesi
  • National Institutes of Health (5ul1tr001067-05)
  • National Institute of Mental Health (R33MH096858)
  • National Institute on Drug Abuse (K05DA031247, R36DA036767)
  • National Center for Advancing Translational Sciences (UL1-TR001067)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
creatine monohydrate, depression, methamphetamine dependence, treatment-resistant depression, anxiety symptoms, phosphorus magnetic resonance spectroscopy, dietary supplementation, gender differences in depression
MeSH terms
Adult, Antidepressive Agents, Brain, Creatine, Depressive Disorder, Female, Humans, Methamphetamine, Middle Aged, Magnetic Resonance Spectroscopy, Phosphocreatine, Pilot Projects, Treatment Outcome, Diagnosis, Dual (Psychiatry), Amphetamine-Related Disorders, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. https://app.cochat.ai/papers/10.1080/15504263.2015.1100471
The paper
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015). Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study. Journal of Dual Diagnosis. https://doi.org/10.1080/15504263.2015.1100471

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.